IQVIA Holdings stock gains on raised Morgan Stanley price target

IQVIA Holdings Inc. stock (ISIN US46266C1053) is trading near USD 271 on the New York Stock Exchange as of September 17, 2026, supported by strong momentum and a higher analyst price target. As GuruFocus reported on September 17, 2026, Morgan Stanley lifted its target from USD 240.00 to USD 270.00, an increase of 12.5 percent.

Analyst target raised and valuation signal

According to GuruFocus on September 17, 2026, Morgan Stanley maintained its positive stance on IQVIA and raised the price target to USD 270.00 from USD 240.00, implying a 12.5 percent upward revision based on its prior estimate. The same overview notes a current IQVIA share price of USD 271.39 and a GF Value, an internal fair-value metric, of USD 248.72, which suggests the stock is roughly 9.1 percent above that valuation benchmark at this level.

This combination of a higher price target and an indicated premium to GF Value highlights a key tension for investors: the Morgan Stanley target now broadly aligns with the market price, while GuruFocus still classifies IQVIA as modestly overvalued versus its long-term fundamentals at a GF Value of USD 248.72 and a spot price of USD 271.39 on September 17, 2026. The 9.1 percent gap offers a concrete reference point for those weighing further upside against valuation risk.

Share-price performance and earnings expectations

MarketBeat reported on September 17, 2026, that IQVIA shares opened at USD 269.54 on the NYSE on that day, giving a detailed snapshot of the stock’s recent trading range. In the same update, MarketBeat noted that sell-side analysts as a group expect IQVIA to deliver earnings per share of USD 11.57 for the current fiscal year 2026, while the company itself has issued guidance for fiscal year 2026 EPS in a range of USD 12.80 to USD 13.00, signaling that management’s outlook stands more than 10 percent above the consensus midpoint.

According to the MarketBeat overview dated September 17, 2026, IQVIA also carries a consensus analyst rating of Moderate Buy and an average target price of USD 243.62 across covered houses. Relative to the current share price around USD 271, this average target is approximately 11 percent below the market, underlining that the Morgan Stanley target of USD 270.00 is now at the upper end of the published range and closely tracks the latest trading level.

Performance over the medium term has been robust. As Zacks highlighted on September 17, 2026, IQVIA stock has risen 60.1 percent over the past six months, significantly outperforming the medical industry’s 4.1 percent return and the S&P 500 Composite’s 14 percent rally over the same period. This six-month gain of 60.1 percent gives investors a clear sense of how strongly the shares have re-rated recently compared with broader benchmarks.

Guidance, fundamentals and risks

In its latest guidance commentary summarized by MarketBeat on September 17, 2026, IQVIA set its fiscal year 2026 EPS guidance at USD 12.80 to USD 13.00. Using the midpoint of USD 12.90, this marks a notable uplift versus the analyst consensus of USD 11.57, a difference of around USD 1.33 per share, or roughly 11.5 percent above expectations. This gap underscores management’s confidence in revenue growth, margin expansion and cost discipline in the current year.

While the MarketBeat alert focuses on earnings, it also implies that investors are already pricing in this stronger outlook, as the current price of about USD 271 on September 17, 2026, corresponds to a forward price-to-earnings multiple in the low 20s based on the company’s own EPS target range. At the guidance midpoint of USD 12.90 and a price near USD 271, IQVIA trades on a forward P/E of approximately 21 times, a level that reflects both its growth profile and the perceived resilience of its data and technology-driven services to the life sciences sector.

A valuation comparison from Tikr on September 17, 2026, places IQVIA’s next-twelve-month EV/revenue multiple at 3.28 times, below Medpace at 5.83 times and Thermo Fisher Scientific at 5.62 times. This suggests that, despite its strong share-price run, IQVIA is still valued at a lower revenue multiple than some peers in adjacent life sciences and contract research segments, a factor that may balance the overvaluation signal indicated by the GF Value metric at USD 248.72.

Stock level and investor takeaway

Per the price snapshots from September 17, 2026, IQVIA Holdings stock is trading around USD 271 on the NYSE, close to the new Morgan Stanley price target of USD 270.00 and visibly above the analyst consensus average target of USD 243.62. For investors, the key figures now are the six-month share-price increase of 60.1 percent, the fiscal year 2026 EPS guidance range of USD 12.80 to USD 13.00 versus consensus of USD 11.57, and the roughly 9.1 percent premium to the GF Value fair-value estimate of USD 248.72 at a spot price of USD 271.39 as of September 17, 2026.

More news and analyses on IQVIA Holdings stock